ONCY ONCOLYTICS BIOTECH INC
Company Analysis
Latest News
Oncolytics to Meet FDA on Registrational Pathway for REO 033 Colorectal Cancer Trial
Oncolytics Biotech provided a clinical and regulatory update for its REO 033 study, which evaluates its drug pelareorep for second-line metastatic colorectal...
🟢 Oncolytics Biotech is trading 10.1% up today on speculative momentum
Oncolytics Biotech is trading 10.1% up at $1.02 today, driven by speculative interest and trading momentum despite a lack of fresh company-specific news or...
🟢 Oncolytics Biotech is trading 5.9% up today, extending a volatile stretch despite no fresh news
Oncolytics Biotech is trading at $0.94 (5.9% up) in pre-market, extending a volatile stretch that included a double-digit gain on July 9 followed by a pullback...
🟢 Oncolytics Biotech is trading 5.9% up today in after-hours trading
Oncolytics Biotech is trading at $0.94 (up 5.9%) in after-hours trading despite a lack of fresh company-specific news or regulatory updates. • The stock has...
🟢 Oncolytics Biotech is trading 10.0% up
Oncolytics Biotech is trading at $0.87, up 10.0% from a comparison close of $0.79 during regular trading. This is a price-action follow-up, so a separate...
🟢 ONCY is trading 6% up today in an after-hours rebound
ONCY is trading at $0.84 (+6%) in after-hours trading, staging a rebound following a weak regular session. • The stock closed at $0.79 on July 8, with the...
🔴 ONCY is trading 5.2% down today amid technical weakness and risk-off sentiment
ONCY is trading 5.2% down today at $0.83 as the stock continues to face pressure from negative technical indicators and broader market trends. • Recent...
🔴 ONCY is trading 5.03% down today with no clear company-specific catalyst
ONCY is trading at $0.90 (-5.03%) following a sharp intraday selloff despite a lack of company-specific news or regulatory updates. • No earnings releases,...